Filtered By:
Infectious Disease: Tuberculosis
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 482 results found since Jan 2013.
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Hypersensitivity Reactions to Non-Beta Lactam Antibiotics
AbstractPurpose of ReviewHypersensitivity reactions (HRs) to non-beta lactam antibiotics (NBLAs) have increased over the last years. Although NBLAs with their broad spectrum are widely used to treat various infections, knowledge about HRs due to these drugs is limited when compared to beta-lactam antibiotics (BLAs). Therefore, we aimed to discuss the structures, subgroups of various NBLAs including fluoroquinolones, macrolides, sulfonamides, first-line anti-tuberculosis agents, 5-nitroimidazols, aminoglycosides, glycopeptides, clindamycin, and tetracyclines, and we also reviewed epidemiology, clinical characteristics, cros...
Source: Current Treatment Options in Allergy - August 26, 2021 Category: Allergy & Immunology Source Type: research
Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases
Vaccine. 2021 Aug 5:S0264-410X(21)00964-6. doi: 10.1016/j.vaccine.2021.07.071. Online ahead of print.ABSTRACTModern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institut...
Source: Vaccine - August 9, 2021 Category: Allergy & Immunology Authors: M Patricia D'Souza Amy C Palin Thomas Calder Hana Golding Steven H Kleinstein Erin L Milliken David O'Connor Georgia Tomaras Jon Warren Cesar Boggiano Source Type: research
Mycobacterium-Induced Th1, Helminths-Induced Th2 Cells and the Potential Vaccine Candidates for Allergic Asthma: Imitation of Natural Infection
Bronchial asthma is one of the most chronic pulmonary diseases and major public health problems. In general, asthma prevails in developed countries than developing countries, and its prevalence is increasing in the latter. For instance, the hygiene hypothesis demonstrated that this phenomenon resulted from higher household hygienic standards that decreased the chances of infections, which would subsequently increase the occurrence of allergy. In this review, we attempted to integrate our knowledge with the hygiene hypothesis into beneficial preventive approaches for allergic asthma. Therefore, we highlighted the studies th...
Source: Frontiers in Immunology - August 3, 2021 Category: Allergy & Immunology Source Type: research
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Microbiological profile in chronic granulomatous disease patients in a single Brazilian primary immunodeficiencies center
CONCLUSION: Staphylococcus sp., Staphylococcus aureus, and Aspergillus sp. were the most frequent agents in this cohort. M. tuberculosis should be considered in endemic areas. Detection of infectious agents drives to find adequate treatment and benefits the evolution of patients with CGD.PMID:34224228 | DOI:10.15586/aei.v49i4.202
Source: Allergologia et Immunopathologia - July 5, 2021 Category: Allergy & Immunology Authors: Aim ée Filippini Bifulco Oliveira Antonio Carlos Pastorino Mayra de Barros Dorna Ana Paula Beltran Moschione Castro Jos é Roberto Mendes Pegler Beni Morgenstern Magda Maria Sales Carneiro-Sampaio Source Type: research
